Details

Autor(en) / Beteiligte

• Martínez-Trillos, Alejandra
• Pinyol, Magda
• Navarro, Alba
• Aymerich, Marta
• Jares, Pedro
• Juan, Manel
• Rozman, María
• Colomer, Dolors
• Delgado, Julio
• Giné, Eva
• González-Díaz, Marcos
• Hernández-Rivas, Jesús M
• Colado, Enrique
• Rayón, Consolación
• Payer, Angel R
• Terol, Maria José
• Navarro, Blanca
• Quesada, Victor
• Puente, Xosé S
• Rozman, Ciril
• López-Otín, Carlos
• Campo, Elías
• López-Guillermo, Armando
• Villamor, Neus

Titel

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

Ist Teil von

• Blood, 2014-06, Vol.123 (24), p.3790-3796

Ort / Verlag

United States

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Mutations in Toll-like receptor (TLR) and myeloid differentiation primary response 88 (MYD88) genes have been found in chronic lymphocytic leukemia (CLL) at low frequency. We analyzed the incidence, clinicobiological characteristics, and outcome of patients with TLR/MYD88 mutations in 587 CLL patients. Twenty-three patients (3.9%) had mutations, 19 in MYD88 (one with concurrent IRAK1 mutation), 2 TLR2 (one with concomitant TLR6 mutation), 1 IRAK1, and 1 TLR5. No mutations were found in IRAK2 and IRAK4. TLR/MYD88-mutated CLL overexpressed genes of the nuclear factor κB pathway. Patients with TLR/MYD88 mutations were significantly younger (83% age ≤50 years) than those with no mutations. TLR/MYD88 mutations were the most frequent in young patients. Patients with mutated TLR/MYD88 CLL had a higher frequency of mutated IGHV and low expression of CD38 and ZAP-70. Overall survival (OS) was better in TLR/MYD88-mutated than unmutated patients in the whole series (10-year OS, 100% vs 62%; P = .002), and in the subset of patients age ≤50 years (100% vs 70%; P = .02). In addition, relative OS of TLR/MYD88-mutated patients was similar to that in the age- and gender-matched population. In summary, TLR/MYD88 mutations identify a population of young CLL patients with favorable outcome.